Our findings provide new insights into the FXR-ER stress interplay in the control of NAFLD and suggest the potential of AT-II as an FXR agonist for the treatment of NAFLD through SERCA2 activation. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.